甲胺通过AMPK信号减轻声纤维化
Jie Cai1, Lucheng Fang1, Peng Zhou1
1Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430000, China.
Inflammation
|October 24, 2024
概括
梅特福明有效地通过激活AMPK信号通路来减少声纤维化. 这项研究显示了甲福胺作为声痕的潜在治疗方法的有希望的结果.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 纤维性疾病 纤维性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 声纤维化带来了重大的治疗挑战.
- 梅特福林在治疗其他纤维状症方面已显示出有效性.
- AMPK信号通路是抗纤维素治疗的潜在目标.
研究的目的:
- 调查甲福明在减少声纤维化中的潜力.
- 探索AMPK信号通路在甲福明对声的抗纤维素作用中的作用.
主要方法:
- 在子中诱导声损伤,随后给予甲福明.
- 纤维化被评估使用组织学染色 (马森三色素) 和分子分析 (免疫组织化学,qPCR,西部斑点).
- 在体外研究中使用了用甲福明和TGF-β1治疗的声纤维细胞,AMPK信号被化合物C抑制.
主要成果:
- 甲胺显著改善了声的结构完整性,并减少了原沉积.
- 甲福明降低了1型原蛋白α1 (COL1A1) 和α-平滑肌肉活性蛋白 (α-SMA) 的表达.
- 甲福明激活了AMPK通路,导致COL1A1,α-SMA,TGF-β,Smad2和Smad3.3的表达减少.
结论:
- 甲胺通过调节AMPK信号通路来减轻声纤维化.
- 这些发现支持甲福明作为声纤维化治疗的潜在治疗剂.
- 进一步的研究可以在这些结果的基础上开发新的治疗策略.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
348
08:01Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
5.7K
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:25cAMP-dependent Protein Kinase Pathways
6.1K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173